User login
Key clinical point: Patients with breast cancer (BC) who did not achieve pathological complete response (pCR) after receiving neoadjuvant chemotherapy (NACT) showed improved survival outcomes after adjuvant aspirin use.
Major finding: The 5-year disease-free survival and distant metastasis-free survival were improved with vs without aspirin use in the whole cohort (adjusted hazard ratio [aHR] 0.48, P = .01; and aHR 0.57, P = .04, respectively) and in higher-risk patients with nodal disease (aHR 0.48, P = .02; and aHR 0.43, P = .008, respectively).
Study details: Findings are from a retrospective study including 637 patients with BC who did not achieve pCR after receiving NACT, of which 138 patients used aspirin after diagnosis.
Disclosures: This study did not receive any funding. Dr. Unni declared serving on advisory boards for various sources.
Source: Johns C et al. Aspirin use is associated with improvement in distant metastases outcome in patients with residual disease after neoadjuvant chemotherapy. Breast Cancer Res Treat. 2023 (Mar 30). Doi: 10.1007/s10549-023-06920-4
Key clinical point: Patients with breast cancer (BC) who did not achieve pathological complete response (pCR) after receiving neoadjuvant chemotherapy (NACT) showed improved survival outcomes after adjuvant aspirin use.
Major finding: The 5-year disease-free survival and distant metastasis-free survival were improved with vs without aspirin use in the whole cohort (adjusted hazard ratio [aHR] 0.48, P = .01; and aHR 0.57, P = .04, respectively) and in higher-risk patients with nodal disease (aHR 0.48, P = .02; and aHR 0.43, P = .008, respectively).
Study details: Findings are from a retrospective study including 637 patients with BC who did not achieve pCR after receiving NACT, of which 138 patients used aspirin after diagnosis.
Disclosures: This study did not receive any funding. Dr. Unni declared serving on advisory boards for various sources.
Source: Johns C et al. Aspirin use is associated with improvement in distant metastases outcome in patients with residual disease after neoadjuvant chemotherapy. Breast Cancer Res Treat. 2023 (Mar 30). Doi: 10.1007/s10549-023-06920-4
Key clinical point: Patients with breast cancer (BC) who did not achieve pathological complete response (pCR) after receiving neoadjuvant chemotherapy (NACT) showed improved survival outcomes after adjuvant aspirin use.
Major finding: The 5-year disease-free survival and distant metastasis-free survival were improved with vs without aspirin use in the whole cohort (adjusted hazard ratio [aHR] 0.48, P = .01; and aHR 0.57, P = .04, respectively) and in higher-risk patients with nodal disease (aHR 0.48, P = .02; and aHR 0.43, P = .008, respectively).
Study details: Findings are from a retrospective study including 637 patients with BC who did not achieve pCR after receiving NACT, of which 138 patients used aspirin after diagnosis.
Disclosures: This study did not receive any funding. Dr. Unni declared serving on advisory boards for various sources.
Source: Johns C et al. Aspirin use is associated with improvement in distant metastases outcome in patients with residual disease after neoadjuvant chemotherapy. Breast Cancer Res Treat. 2023 (Mar 30). Doi: 10.1007/s10549-023-06920-4